TIDEL II Substudy: Early Imatinib-Induced ABCB1 Overexpression in Chronic-Phase CML
Eadie LN et al. The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients: A TIDEL II sub-study. Proc ASH 2015;Abstract 348.
|